Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts

• Publication date: February 2011

Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. Much of the interest in pulmonary delivery of systemic drug therapies is focused on chronic diseases and refractory conditions – aliments that require frequent drug administration for a protracted period of time. While several approaches for delivering active substances to,...

Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. Much of the interest in pulmonary delivery of systemic drug therapies is focused on chronic diseases and refractory conditions – aliments that require frequent drug administration for a protracted period of time. While several approaches for delivering active substances to, and systematically via, the lungs compete in this space, recent advances and investment in powder formulations, particle engineering, and device architecture have positioned dry powder inhalation (DPI) as a formidable challenger to more established pulmonary methods such as metered dose inhalers and nebulizers. While evolving DPI technology and combination therapeutic products continue to have a significant impact on the treatment of upper respiratory diseases and conditions, dry powder inhalers are making strides in applications requiring the systemic delivery of both small and large molecule and engineered macromolecules for the treatment of a range of pathologies.

Highlights

• Analyzes and evaluates Dry Powder Inhalers and competing inhaled drug delivery technologies and assesses the market potential for existing and probable future products

• Examines Dry Powder Inhaler design issues and evolving market factors

• Forecasts the impact of DPI technology and devices on drug delivery markets and projects probable future developments

• Provides forecasts of DPI combination product demand by indication and drug class to 2014

• Profiles Dry Powder Inhalation market participants, their technology, product development activity, and business strategies

Drug Delivery Technology Industry

Executive Summary

The Market Picture for Inhaled Therapeutics

Devices, Formulations and Market Evolution
Established Therapeutic Targets
Emerging Therapies
Demographics and Growth
Competing Technologies
Market Drivers
Risk Factors

Dry Powder Inhalation Technology

Dry Powder Formulations
Dry Powder Particle Technology & Powder Engineering
Dry Powder Formulations
Dry Powder Processing
Dry Powder Packaging
Emerging Formulations
Dry Powder Inhalers
DPI Device Characteristics
DPI Design Parameters

DPI Device Assessments

Acu-Breathe (Respirics)
Aerolizer Novartis)
AIR (Civitas/Alkermes)
Airmax (Teva)
Aspirair (Vectura)
Axahaler (S.M.B.)
Breezhaler (Novartis)
Clickhaler (Vectura)
Conix Dry (3M)
Cricket (Mannkind)
Cyclohaler (Teva)
Diskhaler (GlaxoSmithKline)
Diskus (GlaxoSmithKline)
Dreamboat (Mannkind)
Easyhaler (Orion)
EZ Aer (Aerovance)
Flexhaler (AstraZeneca)
Genuair (Almirall)
Gemini (GSK)
Handihaler Boehringer Ingelheim)
MicroDose (MicroDose Therapeutx)
Next DPI (Chiesi)
Novolizer (Meda)
Oximax (Mantecorp)
Podhaler (Novartis)
Pulmojet (sanofi-aventis)
Pulvinal (Chiesi)
Skyehaler (SKyepharma)
Solis (Sandoz/Novartis)
Taifun (Akela)
Taper Dry (3M)
Trivair (Trimel Bipharma)
Twincaps/Flowcaps (Hovione)
Twisthaler (Schering /Merck)
Turbuhaler (AstraZeneca)

Dry Powder Inhalation – Therapeutic Segment Analysis & Forecasts

Upper Respiratory Indications
Disease Segments
Therapeutic Landscape
Prescribing Trends and Growth Factors
Systemic Drug Delivery
Bioterror
Diabetes
Hereditary Diseases
Cystic Fibrosis
Infectious Diseases
Osteoporosis
Neurology
Pain Management

Market Factors

Device Design
Regulatory Issues
Patient Compliance
The Role of CMOs/CSOs
Healthcare Economics

Company Profiles